Key Points
- Director Evan/ Fa Jones sold shares: On Nov. 25 Jones sold 1,106 Veracyte shares at an average $50.25 (≈$55,577), leaving them with 29,362 shares (a 3.63% ownership decline); they also sold 43,196 shares on Nov. 5 for ≈$1.95M.
- Stock moved lower: VCYT fell 3.4% to $47.71 with ~1.08M shares traded (vs. a ~1.11M average), market cap ~$3.77B and a P/E near 145, with a 1‑year range of $22.61–$50.71.
- Quarterly results and analyst view: Veracyte beat estimates with $0.51 EPS and $131.9M revenue (revenue +13.8% YoY), and analysts rate the stock a "Moderate Buy" with an average target around $43.38.
Veracyte, Inc. (NASDAQ:VCYT - Get Free Report) Director Evan/ Fa Jones sold 1,106 shares of Veracyte stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $50.25, for a total value of $55,576.50. Following the completion of the sale, the director owned 29,362 shares in the company, valued at approximately $1,475,440.50. This represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Evan/ Fa Jones also recently made the following trade(s):
- On Wednesday, November 5th, Evan/ Fa Jones sold 43,196 shares of Veracyte stock. The stock was sold at an average price of $45.06, for a total transaction of $1,946,411.76.
Veracyte Stock Down 3.4%
Shares of NASDAQ:VCYT traded down $1.67 on Thursday, hitting $47.71. The company had a trading volume of 1,081,979 shares, compared to its average volume of 1,110,494. The firm's 50-day simple moving average is $37.47 and its two-hundred day simple moving average is $31.14. The firm has a market capitalization of $3.77 billion, a price-to-earnings ratio of 144.58 and a beta of 2.16. Veracyte, Inc. has a 1 year low of $22.61 and a 1 year high of $50.71.
Veracyte (NASDAQ:VCYT - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.19. Veracyte had a net margin of 5.50% and a return on equity of 6.07%. The company had revenue of $131.87 million for the quarter, compared to analysts' expectations of $124.62 million. During the same quarter in the previous year, the company earned $0.33 earnings per share. Veracyte's quarterly revenue was up 13.8% on a year-over-year basis. Veracyte has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Veracyte, Inc. will post 0.68 EPS for the current year.
Institutional Investors Weigh In On Veracyte
Large investors have recently added to or reduced their stakes in the stock. AlphaQuest LLC lifted its stake in shares of Veracyte by 1,279.9% during the 2nd quarter. AlphaQuest LLC now owns 8,031 shares of the biotechnology company's stock valued at $217,000 after buying an additional 7,449 shares in the last quarter. Strs Ohio purchased a new position in shares of Veracyte in the first quarter valued at about $848,000. Victory Capital Management Inc. boosted its stake in shares of Veracyte by 73.0% in the first quarter. Victory Capital Management Inc. now owns 97,786 shares of the biotechnology company's stock worth $2,899,000 after acquiring an additional 41,248 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Veracyte by 70.1% during the second quarter. Assenagon Asset Management S.A. now owns 830,099 shares of the biotechnology company's stock worth $22,438,000 after purchasing an additional 342,038 shares in the last quarter. Finally, Voya Investment Management LLC lifted its holdings in Veracyte by 79.7% in the 1st quarter. Voya Investment Management LLC now owns 41,452 shares of the biotechnology company's stock worth $1,229,000 after purchasing an additional 18,386 shares in the last quarter.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on the stock. Wall Street Zen upgraded shares of Veracyte from a "buy" rating to a "strong-buy" rating in a report on Sunday, November 16th. Zacks Research raised Veracyte from a "hold" rating to a "strong-buy" rating in a research note on Monday, October 6th. Needham & Company LLC lifted their price target on Veracyte from $41.00 to $44.00 and gave the stock a "buy" rating in a research report on Wednesday, November 5th. Weiss Ratings restated a "hold (c)" rating on shares of Veracyte in a research note on Tuesday. Finally, Canaccord Genuity Group increased their price target on shares of Veracyte from $40.00 to $43.00 and gave the company a "hold" rating in a report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Veracyte currently has an average rating of "Moderate Buy" and an average target price of $43.38.
View Our Latest Report on Veracyte
Veracyte Company Profile
(
Get Free Report)
Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
